Show simple item record

dc.contributor.authorSiller, Anita
dc.contributor.authorSeekircher, Lisa
dc.contributor.authorWachter, Gregor A
dc.contributor.authorAstl, Manfred
dc.contributor.authorTschiderer, Lena
dc.contributor.authorPfeifer, Bernhard
dc.contributor.authorGaber, Manfred
dc.contributor.authorSchennach, Harald
dc.contributor.authorWilleit, Peter
dc.date.accessioned2022-03-11T09:00:24Z
dc.date.available2022-03-11T09:00:24Z
dc.date.issued2022-03-09
dc.identifier.issn1999-4915
dc.identifier.urihttps://www.repository.cam.ac.uk/handle/1810/334881
dc.description.abstract<jats:p>There is uncertainty about the seroprevalence of anti-SARS-CoV-2 antibodies in the general population of Austria and about the waning of antibodies over time. We conducted a seroepidemiological study between June 2020 and September 2021, enrolling blood donors aged 18–70 years across Tyrol, Austria (participation rate: 84.0%). We analyzed serum samples for antibodies against the spike or the nucleocapsid proteins of SARS-CoV-2. We performed a total of 47,363 samples taken from 35,193 individuals (median age, 43.1 years (IQR: 29.3–53.7); 45.3% women; 10.0% with prior SARS-CoV-2 infection). Seroprevalence increased from 3.4% (95% CI: 2.8–4.2%) in June 2020 to 82.7% (95% CI: 81.4–83.8%) in September 2021, largely due to vaccination. Anti-spike IgG seroprevalence was 99.6% (95% CI: 99.4–99.7%) among fully vaccinated individuals, 90.4% (95% CI: 88.8–91.7%) among unvaccinated individuals with prior infection and 11.5% (95% CI: 10.8–12.3%) among unvaccinated individuals without known prior infection. Anti-spike IgG levels were reduced by 44.0% (95% CI: 34.9–51.7%) at 5–6 months compared with 0–3 months after infection. In fully vaccinated individuals, they decreased by 31.7% (95% CI: 29.4–33.9%) per month. In conclusion, seroprevalence in Tyrol increased to 82.7% in September 2021, with the bulk of seropositivity stemming from vaccination. Antibody levels substantially and gradually declined after vaccination or infection.</jats:p>
dc.languageen
dc.publisherMDPI AG
dc.subjectSARS-CoV-2
dc.subjectseroprevalence
dc.subjectanti-S IgG
dc.subjectanti-N IgG
dc.subjectblood donors
dc.titleSeroprevalence, Waning and Correlates of Anti-SARS-CoV-2 IgG Antibodies in Tyrol, Austria: Large-Scale Study of 35,193 Blood Donors Conducted between June 2020 and September 2021
dc.typeArticle
dc.date.updated2022-03-11T09:00:23Z
prism.issueIdentifier3
prism.publicationNameViruses
prism.volume14
dc.identifier.doi10.17863/CAM.82318
dcterms.dateAccepted2022-03-07
rioxxterms.versionofrecord10.3390/v14030568
rioxxterms.versionVoR
rioxxterms.licenseref.urihttps://creativecommons.org/licenses/by/4.0/
dc.contributor.orcidTschiderer, Lena [0000-0001-7988-853X]
dc.contributor.orcidWilleit, Peter [0000-0002-1866-7159]
dc.identifier.eissn1999-4915
pubs.funder-project-idLand Tirol (Not available, Not available)
cam.issuedOnline2022-03-09


Files in this item

Thumbnail
Thumbnail
Thumbnail

This item appears in the following Collection(s)

Show simple item record